Vistagen (VTGN) Q1 R&D Expense Jumps 54%

Key Points

• EPS (GAAP) matched analyst estimates at $(0.47) in Q1 FY2026, reflecting the continued R&D-intensive profile of operations.

• Revenue (GAAP) of $0.24 million exceeded expectations (estimate: $0.0 million) in Q1 FY2026, though topline remains non-product and minimal.

• Research and development expense (GAAP) rose 53.9% year over year in FY2025. R&D expense was $11.7 million for the three months ended June 30, 2025, compared to $7.6 million for the same period in 2024. The increase was primarily driven by higher research, development, contract manufacturing expenses, and headcount related to the U.S. registration-directed PALISADE Program for fasedienol in SAD.

• These 10 stocks could mint the next wave of millionaires ›

Vistagen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing intranasal therapies for neuropsychiatric and women’s health conditions, released its fiscal 2026 first quarter earnings on August 7, 2025. The company’s top-line results largely matched expectations: earnings per share (EPS) (GAAP) came in at $(0.47) in Q1 FY2026, directly in line with consensus estimates, while reported revenue of $0.24 million (GAAP) in Q1 FY2026 surpassed the estimate of $0.0 million. R&D spending increased significantly to support ongoing phase 3 trials. Net loss was $51.4 million for the year ended March 31, 2025, compared to $29.4 million for the year ended March 31, 2024. The quarter marked continued progress in advancing lead clinical programs, with particular attention on upcoming data for its social anxiety disorder therapy, fasedienol.

Source: Analyst estimates for the quarter provided by FactSet.

Company Profile and Recent Focus

Vistagen Therapeutics is a biopharmaceutical company aiming to develop new treatments for conditions such as social anxiety disorder (SAD), major depressive disorder (MDD), and symptoms related to menopause. Its clinical approach uses “pherine” compounds -- novel, intranasal neuroactive therapies intended to modulate brain circuits without systemic absorption, in contrast to traditional psychiatric drugs.

Recently, the company has focused on advancing its lead program, fasedienol, through pivotal phase 3 trials for social anxiety disorder. Other programs include PH80 (for menopausal hot flashes) and itruvone (for MDD), each leveraging the same “nose-to-brain” platform. Success will depend largely on clinical trial outcomes, the pace of regulatory progress, and ultimately, the ability to reach the market with differentiated therapies addressing high unmet needs.

Quarterly Review and Key Developments

During the quarter, The company reported revenue (GAAP) of $0.24 million in Q1 FY2026, reflecting non-product income given that product commercialization has not yet begun. Net loss was $15.1 million for the three months ended June 30, 2025, compared to $10.7 million for the same period in 2024, driven primarily by higher investment in research and development as late-stage clinical programs expanded.

This rise came as the company pushed ahead with its pivotal U.S. registration-directed PALISADE-3 and PALISADE-4 phase 3 trials for fasedienol. Management attributed the uptick in costs to increased clinical trial activity, additional research personnel, and ongoing contract manufacturing associated with the fasedienol program. General and administrative expense (GAAP) declined slightly to $4.4 million in Q1 FY2026.

The lead program, fasedienol nasal spray, is a non-systemic intranasal therapy for acute treatment of social anxiety disorder. More than 30 million U.S. adults are estimated to be affected by SAD, and currently, there are no U.S. Food and Drug Administration (FDA)-approved acute treatments. Vistagen expects topline results from the PALISADE-3 trial in the fourth quarter of 2025, followed by PALISADE-4 results in the first half of 2026. The company stated, “•Vistagen believes either PALISADE-3 or PALISADE-4, if successful, together with the positive results from PALISADE-2, may establish substantial evidence of the effectiveness of fasedienol in support of a potential New Drug Application (NDA) submission”

In women’s health, PH80 nasal spray -- another pherine product -- has shown positive exploratory phase 2A results for treating vasomotor symptoms (hot flashes) associated with menopause, a condition affecting up to 80% of menopausal women in the U.S, according to SWAN (Study of Women Across the Nation) and other published studies. Vistagen is preparing for further development of PH80 by filing an Investigational New Drug Application with the FDA. Additionally, itruvone nasal spray for MDD has advanced in planning for new phase 2 trials. Fast Track designation, which can speed up reviews, is in place for both fasedienol and itruvone.

The company appointed a new Chief Corporate Development Officer, signaling attention to future commercial and partnership strategies as clinical programs move closer to possible approval and launch. Cash, cash equivalents, and marketable securities totaled $63.2 million as of June 30, 2025 (Q1 FY2026), down from $80.5 million (GAAP) as of Q4 FY2025.

Looking Ahead: Guidance and Upcoming Milestones

Management did not provide specific forward financial guidance for fiscal 2026 in the earnings release. Instead, the focus remains on the execution and outcome of its pivotal clinical trials, especially for fasedienol. Announcements of trial completion and topline data will be the key milestones in the coming quarters.

Investors and observers should track the progress of the PALISADE-3 and PALISADE-4 trial readouts, as successful results would be critical for potential New Drug Application submission and future commercial plans.

Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,046%* — a market-crushing outperformance compared to 181% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of August 4, 2025

JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.